Published in Clin J Am Soc Nephrol on March 01, 2008
Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am J Transplant (2012) 2.46
Ultrasound prevents renal ischemia-reperfusion injury by stimulating the splenic cholinergic anti-inflammatory pathway. J Am Soc Nephrol (2013) 1.76
Complete steroid avoidance is effective and safe in children with renal transplants: a multicenter randomized trial with three-year follow-up. Am J Transplant (2012) 1.45
Subclinical inflammation and chronic renal allograft injury in a randomized trial on steroid avoidance in pediatric kidney transplantation. Am J Transplant (2012) 1.18
Recent developments in kidney transplantation--a critical assessment. Am J Transplant (2009) 1.02
A simplified immune suppression scheme leads to persistent micro-dystrophin expression in Duchenne muscular dystrophy dogs. Hum Gene Ther (2011) 1.00
Safety of human neural stem cell transplantation in chronic spinal cord injury. Stem Cells Transl Med (2013) 0.97
Inhibitors of C5 complement enhance vaccinia virus oncolysis. Cancer Gene Ther (2013) 0.83
Validation of an LC-MS/MS method to determine five immunosuppressants with deuterated internal standards including MPA. BMC Clin Pharmacol (2012) 0.82
Steroids in kidney transplant patients. Semin Immunopathol (2011) 0.80
Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation. World J Gastroenterol (2014) 0.75
Calcineurin inhibitor sparing strategies in renal transplantation, part one: Late sparing strategies. World J Transplant (2014) 0.75
A prospective, multinational pharmacoepidemiological study of clinical conversion to sirolimus immunosuppression after renal transplantation. J Transplant (2012) 0.75
Immunomodulatory drugs: oral and systemic adverse effects. Med Oral Patol Oral Cir Bucal (2014) 0.75
Impact of irradiation and immunosuppressive agents on immune system homeostasis in rhesus macaques. Clin Exp Immunol (2015) 0.75
Treatment with Tacrolimus and Sirolimus Reveals No Additional Adverse Effects on Human Islets In Vitro Compared to Each Drug Alone but They Are Reduced by Adding Glucocorticoids. J Diabetes Res (2016) 0.75
The over-exaggerated chronic nephrotoxicity of calcineurin inhibitors. Arab J Urol (2012) 0.75
Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med (1999) 15.69
Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med (2007) 9.44
The natural history of chronic allograft nephropathy. N Engl J Med (2003) 8.70
Strategies to improve long-term outcomes after renal transplantation. N Engl J Med (2002) 6.76
Costimulation blockade with belatacept in renal transplantation. N Engl J Med (2005) 4.86
Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant (2004) 4.04
Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet (2000) 2.81
Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation (1999) 2.81
Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc (2003) 2.71
Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation (1995) 2.67
Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant (2007) 2.61
Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant (2007) 2.46
Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation (1996) 2.24
Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant (2006) 2.22
Long-term graft outcomes after steroid withdrawal in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation (2007) 2.18
De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant (2004) 2.17
Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation (2000) 1.90
Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation (2001) 1.85
Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant (2006) 1.83
Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant (2007) 1.64
Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation (2002) 1.50
Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation (2003) 1.46
Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study. Am J Transplant (2006) 1.44
A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation (2001) 1.41
Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation (2005) 1.39
Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation (2000) 1.33
Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil--a prospective randomized study. Steroid Withdrawal Study Group. Transplantation (1999) 1.29
Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results. Am J Transplant (2005) 1.29
Transplant data: sources, collection, and caveats. Am J Transplant (2004) 1.28
Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation (2002) 1.26
Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation (2003) 1.23
Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation (2004) 1.20
Prednisone-free maintenance immunosuppression-a 5-year experience. Am J Transplant (2005) 1.17
A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation (2005) 1.14
Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant (2004) 1.12
Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant (2002) 1.11
Why hasn't eliminating acute rejection improved graft survival? Annu Rev Med (2007) 1.10
A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis. Am J Transplant (2005) 1.09
Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol (2005) 1.06
Long-term immunosuppression, without maintenance prednisone, after kidney transplantation. Ann Surg (2004) 1.04
Long-term graft survival with neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol (2003) 1.03
Molecular and structural consequences of early renal allograft injury. Kidney Int (2002) 1.03
Steroid avoidance regimens: a comparison of outcomes with maintenance steroids versus continued steroid avoidance in recipients having an acute rejection episode. Am J Transplant (2007) 1.02
Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation. Am J Transplant (2007) 1.02
Molecular comparison of calcineurin inhibitor-induced fibrogenic responses in protocol renal transplant biopsies. J Am Soc Nephrol (2006) 1.02
A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. Am J Transplant (2005) 1.00
Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant (2005) 0.99
Outcome at 3 years with a prednisone-free maintenance regimen: a single-center experience with 349 kidney transplant recipients. Am J Transplant (2004) 0.97
Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study. Transplantation (2005) 0.97
Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int (2005) 0.97
Histopathology of cyclosporine nephrotoxicity. Transplant Proc (1988) 0.96
Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol (2002) 0.95
Steroid-free immunosuppression in kidney transplantation: an editorial review. Am J Transplant (2002) 0.95
An alternate mechanism of glucocorticoid anti-proliferative effect: promotion of a Th2 cytokine-secreting profile. Clin Transplant (1999) 0.95
Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression. Am J Transplant (2005) 0.94
Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation (2001) 0.94
Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. Am J Kidney Dis (1991) 0.94
Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results. Am J Transplant (2006) 0.94
Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation (2003) 0.94
Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation (2003) 0.93
A prospective randomized trial of prednisone versus no prednisone maintenance therapy in cyclosporine-treated and azathioprine-treated renal transplant patients. Transplantation (1990) 0.93
A prospective, pilot study of early corticosteroid cessation in high-immunologic-risk patients: the Cincinnati experience. Transplant Proc (2005) 0.92
Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant (2003) 0.92
Rapid discontinuation of prednisone in higher-risk kidney transplant recipients. Transplantation (2004) 0.90
Renal transplantation: a half century of success and the long road ahead. J Am Soc Nephrol (2004) 0.89
Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology. Am J Transplant (2007) 0.89
Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant (2004) 0.89
Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival. Am J Transplant (2004) 0.88
Elective cyclosporine withdrawal after renal transplantation. A meta-analysis. JAMA (1993) 0.88
Withdrawal of steroid immunosuppression in renal transplant recipients. Transplantation (1988) 0.88
The use of cyclosporine in living-related renal transplantation. Donor-specific hyporesponsiveness and steroid withdrawal. Transplantation (1984) 0.88
Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol (2004) 0.87
Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation (2003) 0.87
A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation (2001) 0.87
Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies. Clin Transplant (2005) 0.87
Toxicity-sparing protocols using mycophenolate mofetil in renal transplantation. Transplantation (2005) 0.86
Mycophenolate mofetil in solid-organ transplantation. Expert Opin Pharmacother (2003) 0.86
A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. Transplantation (2006) 0.86
Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation (2007) 0.85
Steroid-free immunosuppression in renal transplantation: a long-term follow-up of 100 consecutive patients. Transplantation (2001) 0.85
Mycophenolate mofetil monotherapy: an example of a safe nephrotoxicity/atherogenicity-free immunosuppressive maintenance regimen in a selected group of kidney-transplanted patients. Transplant Proc (2000) 0.84
Short-term experience with early steroid withdrawal in African-American renal transplant recipients. Am J Transplant (2006) 0.84
Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation (1991) 0.84
Steroid withdrawal in mycophenolate mofetil-treated renal allograft recipients. Transplantation (1997) 0.84
Effect of sirolimus withdrawal in patients with deteriorating renal function. Am J Transplant (2004) 0.82
Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. Transplantation (2001) 0.82
Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Transplantation (2006) 0.81
Histopathologic findings associated with a chronic, progressive decline in renal allograft function. Kidney Int (1991) 0.81
A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation: comparison of two maintenance immunosuppression protocols: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation (2002) 0.81
Sirolimus and cyclosporin for renal transplantation. Lancet (2000) 0.81
Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine-treated renal transplant recipients. Transplantation (1992) 0.80
Rapid steroid withdrawal versus standard steroid therapy in patients treated with basiliximab, cyclosporine, and mycophenolate mofetil for the prevention of acute rejection in renal transplantation. Transplant Proc (2001) 0.79
Excellent short-term results with steroid-free maintenance immunosuppression in low-risk simultaneous pancreas-kidney transplantation. Arch Surg (2003) 0.78
Recipient age and mycophenolate mofetil as the main determinants of outcome after steroid withdrawal: analysis of long-term follow-up in renal transplantation. Transplantation (2005) 0.78
Elective cyclosporine withdrawal 1 year after renal transplantation. Am J Kidney Dis (1994) 0.78
Low-dose mycophenolate mofetil is an effective and safe treatment to permit phased reduction in calcineurin inhibitors in chronic allograft nephropathy. Transplantation (2005) 0.78
Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up. Transpl Int (2002) 0.78
Mycophenolate mofetil-based immunosuppressive minimization and withdrawal strategies in renal transplantation: possible risks and benefits. Curr Opin Nephrol Hypertens (2006) 0.77
Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med (2016) 5.31
Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect (2012) 3.24
Deceased donor kidney and liver transplantation to nonresident aliens in the United States. Transplantation (2007) 2.11
Which renal transplant candidates should accept marginal kidneys in exchange for a shorter waiting time on dialysis? Clin J Am Soc Nephrol (2006) 1.92
Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004-2008. Diagn Microbiol Infect Dis (2012) 1.88
Half of kidney transplant candidates who are older than 60 years now placed on the waiting list will die before receiving a deceased-donor transplant. Clin J Am Soc Nephrol (2009) 1.77
Poor predictive value of serum creatinine for renal allograft loss. Am J Transplant (2003) 1.74
The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis (2012) 1.61
Barriers to evaluation and wait listing for kidney transplantation. Clin J Am Soc Nephrol (2011) 1.54
No robust conclusions to be drawn from clinical trials in the absence of an adequate control group. Transpl Int (2007) 1.39
Death after graft loss: an important late study endpoint in kidney transplantation. Am J Transplant (2002) 1.33
Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol (2006) 1.33
Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. Nephrol Dial Transplant (2007) 1.30
The broad spectrum of quality in deceased donor kidneys. Am J Transplant (2005) 1.22
The association of candidate mortality rates with kidney transplant outcomes and center performance evaluations. Transplantation (2008) 1.19
The pivotal impact of center characteristics on survival of candidates listed for deceased donor kidney transplantation. Med Care (2009) 1.15
Long-term graft survival with neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol (2003) 1.03
Are we frozen in time? Analysis of the utilization and efficacy of pulsatile perfusion in renal transplantation. Am J Transplant (2005) 1.02
Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transpl Int (2009) 1.01
Access to quality: evaluation of the allocation of deceased donor kidneys for transplantation. J Am Soc Nephrol (2005) 0.98
Renal allograft survival in patients with oxalosis. Transplantation (2002) 0.98
Gender imbalance in living donor renal transplantation. Transplantation (2002) 0.97
Effects of blood transfusions given after renal transplantation. Transplantation (2009) 0.94
Renal allograft survival in transplant recipients with focal segmental glomerulosclerosis. Am J Transplant (2003) 0.94
Kidney allograft survival: the long and short of it. Nephrol Dial Transplant (2011) 0.91
The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease. Haematologica (2008) 0.91
Obesity and kidney transplantation. Semin Nephrol (2013) 0.91
Calcineurin inhibitors in kidney transplantation: friend or foe? Curr Opin Nephrol Hypertens (2011) 0.89
The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. Transplantation (2005) 0.89
Renal transplantation: a half century of success and the long road ahead. J Am Soc Nephrol (2004) 0.89
Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. Nephrol Dial Transplant (2011) 0.89
Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium. Clin Transplant (2005) 0.88
Renal transplantations performed using non-heart-beating organ donors: going back to the future? Transplantation (2002) 0.87
Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graft-versus-host disease. Blood (2004) 0.87
Overview of large database analysis in renal transplantation. Am J Transplant (2003) 0.86
The effects of renal transplantation on peripheral blood dendritic cells. Clin Transplant (2005) 0.84
Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients. Transplantation (2014) 0.83
The relationship between diabetes and infectious hospitalizations in renal transplant recipients. Diabetes Care (2006) 0.83
Factors associated with long-term renal allograft survival. Ther Drug Monit (2002) 0.83
Effect of sirolimus withdrawal in patients with deteriorating renal function. Am J Transplant (2004) 0.82
Association between admission hyperglycemia and length of stay after renal transplantation. Endocr Pract (2011) 0.81
Immunosuppressive strategies to improve outcomes of kidney transplantation. Semin Nephrol (2007) 0.81
Calcineurin inhibitor-free immunosuppression in kidney transplantation. Transpl Int (2007) 0.81
Pharmacokinetic principles of immunosuppressive drugs. Am J Transplant (2005) 0.80
Long-term outcomes of kidney transplantation in recipients 60 years of age and older at the University of Florida. Clin Transpl (2005) 0.80
Interleukin 12 is associated with reduced relapse without increased incidence of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2005) 0.79
Obesity and kidney transplantation. Contrib Nephrol (2006) 0.79
Best allograft survival from share-35 kidney donors occurs in middle-aged adults and young children-an analysis of OPTN data. Transplantation (2013) 0.78
Prolonged immunosuppression preserves nonsensitization status after kidney transplant failure. Transplantation (2014) 0.77
Renal function with cyclosporine C2 monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipients. Clin Transplant (2007) 0.77
Kidney-transplant rejection and anti-MICA antibodies. N Engl J Med (2008) 0.77
Effect of IVIG administration on complement activation and HLA antibody levels. Transpl Int (2010) 0.76
Increased levels of tumor necrosis factor alpha are associated with an increased risk of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2005) 0.76
Should we be performing pancreas transplants? Am J Transplant (2004) 0.75
Use of intravenous immune globulin and rituximab for desensitization of highly human leukocyte antigen-sensitized patients awaiting kidney transplantation. Transplantation (2010) 0.75
Mycophenolate sodium does not reduce the incidence of GI adverse events compared with mycophenolate mofetil. Am J Transplant (2005) 0.75
Response to "Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared with lisinopril". Transplantation (2002) 0.75
Comparable barriers to access to kidney transplantation across national lines. Transplantation (2009) 0.75
Interventional trials involving patients cannot be performed safely without a control group treated with the standard of care. Transplantation (2007) 0.75
Mycophenolic acid exposure in high- and low-weight renal transplant patients after dosing with mycophenolate mofetil in the Opticept trial. Ther Drug Monit (2010) 0.75
Mycophenolate mofetil: long-term outcomes in solid organ transplantation. Expert Rev Clin Immunol (2006) 0.75
Mortality risk assessment after renal transplantation. Clin Transpl (2002) 0.75